Medicago Shareholders Approve Arrangement with Mitsubishi Tanabe Pharma Corporation

News - Medicago is pleased to annouce that its shareholders have approved, during today's special meeting of its shareholders, the resolution authorizing the previously announced plan of arrangement involving the Company, Mitsubishi Tanabe Pharma Corporation (MTPC) and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC.

DiagnoCure Appoints Richard Bordeleau as Senior Advisor to the Board

News - DiagnoCure announces the appointment of Mr. Richard Bordeleau as Senior Advisor to the Company effective September 1, 2013. Mr. Bordeleau will act as an executive in residence and report directly to DiagnoCure’s board of directors. In collaboration with Company management, Mr. Bordeleau’s initial mandate will be to identify and implement short term actions aimed at increasing shareholder value, and also to evaluate mid to long term scenarios optimizing corporate value.

Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108)

News - Aeterna Zentaris announces that the first patient has been recruited and dosed for the Phase 3 ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with endometrial cancer resistant to platinum/taxane-based chemotherapy.

Aeterna Zentaris to Raise US$7.8 Million in Registered Direct Offering

News - Aeterna Zentaris announces that it has received commitments from institutional investors to purchase US$7.8 million of securities in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such investors an aggregate of approximately 5.2 million common shares of its capital at a price of US$1.50 per share and issue warrants to acquire an aggregate of approximately 2.6 million common shares at an exercise price of US$1.85 per share.

Renowned Chemistry of love speaker organizes event in Québec City

News - The Québec City Convention Centre will welcome the International Symposium on Macrocyclic and Supramolecular Chemistry (ISMSC) 2018. More than 600 delegates will gather in Québec City July 8 to 12, 2018. Mr Normand Voyer*, chemist, professor in the Department of Chemistry at Université Laval and Director of PROTEO, convinced board members to hold the Symposium in Québec City. Mr Voyer is a renowned speaker and has given over 100 lectures to more than 20,000 people. The subject? The Chemistry of love.*

GenePOC, Molecular Platform selected by the Canadian food diagnostics industry for the rapid detection of E. coli from beef at food processing facilities.

News - Genome Alberta is pleased to announce on behalf of our funding partners the Alberta Livestock and Meat Agency, Alberta Innovates Bio Solutions, Genome Canada, Genome Quebec, and the Ontario Ministry of Agriculture and Food and the Ministry of Rural Affairs, the results of our collective funding competition for the rapid detection of pathogenic E.coli. Each of the two successful applications will receive $500,000 in new funding. The successful projects will leverage this investment with additional funding to bring the total investment to $1.6 million over the 18 month life of the projects

Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M

News - Medicago announces that it has entered into a definitive arrangement agreement with Mitsubishi Tanabe Pharma Corporation whereby MTPC will acquire all of the issued and outstanding common shares of Medicago, other than the Shares currently held by Philip Morris Investments B.V.

INESSS and Quebec International join forces for the inaugural Health Innovation Week

Press releases - The National Institute for Excellence in Health and Social Services (INESSS) and Quebec International are proud to announce their collaboration on various events during the inaugural Health Innovation Week. The organizations will be holding three events in Quebec City on December 3, 4 and 5, 2013: the Evaluation and Innovative Technology Forum (organized by the INESSS), along with the Quebec City Health Industry Forum and Quebec Seeks Solutions – Health Edition (both organized by Quebec International).

Immune Design and Medicago Announce License Agreement and Collaboration

News - Immune Design, a leader in the field of therapeutic vaccines for cancer, infectious diseases and allergy, and Medicago announced that they have entered a license agreement providing Medicago the use and commercialization of Immune Design's proprietary synthetic Toll-like Receptor 4 agonist, Glucopyranosyl Lipid A (GLA). Medicago has the option to use Immune Design's molecular adjuvant in its vaccines for various pandemic influenza strains.

Plant-based Methods Could Help Fight Flu, Replace Vaccines

News - Medicago Inc, a Quebec City-based biopharmaceutical company, received a patent from the European Patent Office (EPO) that gives the company sole right to produce flu vaccine-like particles in plants this week.


Jean-MichelGarroLife Sciences

More details


Subscribe to our newsletter for interesting news and information.

Print this page